Evidence map›Paper›PMID 39006315›Full record

Trial reportOpen forum infectious diseases2024

Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non-

Kelly R Reveles, Anne J Gonzales-Luna, Yoav Golan, Carolyn D Alonso, Beth Guthmueller, Xing Tan, Monique R Bidell, Victoria Pokhilko, Carl V Crawford, Andrew M Skinner

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02589847 (An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02589847 phase2completednot on this map

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

TypeinterventionalSponsorRebiotix Inc.Ran2015 to 2019Enrolled272ConditionsClostridium Difficile InfectionArmsRBX2660, Standard of Care Antibiotics
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Newer Therapeutics to Selectively KillInfectious disease reports · 2026
    Review
  3. Probiotic characteristics and whole genome sequencing ofFrontiers in veterinary science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kelly R RevelesCollege of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
Anne J Gonzales-LunaDepartment of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, Texas, USA.
Yoav GolanDepartment of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
Carolyn D AlonsoDivision of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Beth GuthmuellerRebiotix Inc, a Ferring Company, Roseville, Minnesota, USA.
Xing TanFerring Pharmaceuticals, Parsippany, New Jersey, USA.
Monique R BidellFerring Pharmaceuticals, Parsippany, New Jersey, USA.
Victoria PokhilkoFerring Pharmaceuticals, Parsippany, New Jersey, USA.
Carl V CrawfordDivision of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA.
Andrew M SkinnerDepartment of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah, USA.

Funding

San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1M
Epidemiological and Genomic Characteristics of the Widely Disseminated C. difficile Strain, REA Group YIK2BX005609 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI Andrew Michael Skinner · 2023 to 2026
–
BLRD VA IK2 BX005609
6 · The paper itself

Abstract

Background: Antibiotic use is a major risk factor for recurrent Methods: Participants in PUNCH™ Open-Label who received non-CDI antibiotics after RBL administration were included in this subgroup analysis. Treatment response was defined as the absence of CDI diarrhea needing retreatment at the last evaluable time point (8 weeks, 6 months, 1 year, or 2 years) after RBL administration. Results: Among participants from PUNCH™ Open-Label, 43 received non-CDI antibiotics after RBL administration but before CDI recurrence as evaluated over a 2-year period. Across all evaluable time points, 86% (37/43) of participants had a treatment response regardless of when non-CDI antibiotic exposure occurred. Treatment response was sustained for a median 470 days (IQR, 212-648) from the first day of non-CDI antibiotic use. Most participants (5/6) with CDI recurrences received a high-risk antibiotic. Conclusions: RBL remained efficacious in participants with a history of recurrent CDI after subsequent non-CDI antibiotic exposure. Clinical Trials Registration: NCT02589847 (https://clinicaltrials.gov/study/NCT02589847).

Indexed as

antibioticsclinical trialsClostridioides difficile infectionmicrobiota-based therapyrecurrence

Identifiers

PMID39006315
PMCPMC11244191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.